Gene · 5313
Papers2,223
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 2,223
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PKM2 Modulation in Head and Neck Squamous Cell Carcinoma. | Int J Mol Sci | 2022 | 35054968 | PubTator, text mining | PubMed |
| Alpha-solanine Anti-tumor Effects in Non-small Cell Lung Cancer Through Regulating the Energy Metabolism Pathway. | Recent Pat Anticancer Drug Discov | 2022 | 35049438 | PubTator, text mining | PubMed |
| Probing altered enzyme activity in the biochemical characterization of cancer. | Biosci Rep | 2022 | 35048115 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma. | J Oncol | 2022 | 35047040 | PubTator, text mining | PubMed |
| Proteomic profiling identifies novel diagnostic biomarkers and molecular subtypes for mucinous tubular and spindle cell carcinoma of the kidney. | J Pathol | 2022 | 35043389 | PubTator, text mining | PubMed |
| Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. | J Pharmacol Exp Ther | 2022 | 35031585 | PubTator, text mining | PubMed |
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. | Clin Pharmacol Drug Dev | 2022 | 35019238 | PubTator, text mining | PubMed |
| Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD. | Am J Hematol | 2022 | 34989415 | PubTator, text mining | PubMed |
| iTRAQ-based quantitative proteomics analysis of Sprague-Dawley rats liver reveals perfluorooctanoic acid-induced lipid metabolism and urea cycle dysfunction. | Toxicol Lett | 2022 | 34958885 | PubTator, text mining | PubMed |
| Proteomic analysis of alcohol-associated hepatitis reveals glycoprotein NMB (GPNMB) as a novel hepatic and serum biomarker. | Alcohol | 2022 | 34923085 | PubTator, text mining | PubMed |
| ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth. | Cancer Res | 2022 | 34921016 | PubTator, text mining | PubMed |
| Pyruvate metabolism guides definitive lineage specification during hematopoietic emergence. | EMBO Rep | 2022 | 34914165 | PubTator, text mining | PubMed |
| Pyruvate kinase M2 (PKM2) improve symptoms of post-ischemic stroke depression by activating VEGF to mediate the MAPK/ERK pathway. | Brain Behav | 2022 | 34898024 | PubTator, text mining | PubMed |
| Targeting cancer metabolism in the era of precision oncology. | Nat Rev Drug Discov | 2022 | 34862480 | PubTator, text mining | PubMed |
| Severe acute respiratory syndrome coronavirus 2 causes lung inflammation and injury. | Clin Microbiol Infect | 2022 | 34861410 | PubTator, text mining | PubMed |
| Genomic comparisons between hepatocarcinogenic and non-hepatocarcinogenic organophosphate insecticides in the mouse liver. | Toxicology | 2022 | 34813904 | PubTator, text mining | PubMed |
| Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. | Blood Adv | 2022 | 34807970 | PubTator, text mining | PubMed |
| Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status. | Hepatol Commun | 2022 | 34687175 | PubTator, text mining | PubMed |
| Mutation of the murine Prickle1 (R104Q) causes phenotypes analogous to human symptoms of epilepsy and autism. | Exp Neurol | 2022 | 34597683 | PubTator, text mining | PubMed |
| Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. | Blood Adv | 2022 | 34470054 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5313/papers?page=29